Aptevo Therapeutics Stock Forecast, Price & News

-0.25 (-1.13 %)
(As of 05/11/2021 04:30 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume55,118 shs
Average Volume54,329 shs
Market Capitalization$97.23 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics logo

About Aptevo Therapeutics

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for AML and myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company is also developing APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:APVO
Year FoundedN/A

Sales & Book Value

Annual Sales$32.42 million
Book Value$3.66 per share


Net Income$-40,450,000.00




Market Cap$97.23 million
Next Earnings Date5/12/2021 (Estimated)


Overall MarketRank

1.31 out of 5 stars

Medical Sector

829th out of 2,045 stocks

Pharmaceutical Preparations Industry

389th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

Is Aptevo Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aptevo Therapeutics?

Wall Street analysts have given Aptevo Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aptevo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 147,300 shares, a decline of 19.8% from the March 15th total of 183,600 shares. Based on an average trading volume of 63,100 shares, the days-to-cover ratio is presently 2.3 days. Currently, 3.6% of the company's stock are short sold.
View Aptevo Therapeutics' Short Interest

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for Aptevo Therapeutics

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings data on Tuesday, March, 30th. The biotechnology company reported ($1.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.71.
View Aptevo Therapeutics' earnings history

How has Aptevo Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APVO shares have increased by 5,102.4% and is now trading at $21.85.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APVO?

1 analysts have issued 12-month price objectives for Aptevo Therapeutics' shares. Their forecasts range from $32.00 to $32.00. On average, they expect Aptevo Therapeutics' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price.
View analysts' price targets for Aptevo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 59, Pay $779.77k)
  • Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 55, Pay $533.81k)
  • Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 64, Pay $485.68k)
  • Ms. Stacey Jurchison, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Heather Boussios, Acting Gen. Counsel & Assistant Sec.
  • Ms. Censia Pottorf, VP of HR

Who are some of Aptevo Therapeutics' key competitors?

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.29%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Kevin C Tang, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi.
View institutional ownership trends for Aptevo Therapeutics

Which major investors are selling Aptevo Therapeutics stock?

APVO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Aptevo Therapeutics
or view top insider-selling stocks.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $21.85.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics has a market capitalization of $97.23 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis.

How many employees does Aptevo Therapeutics have?

Aptevo Therapeutics employs 58 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is

Where are Aptevo Therapeutics' headquarters?

Aptevo Therapeutics is headquartered at 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]

This page was last updated on 5/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.